Reflections on the Lack of Consideration of Ethnic Ancestry to Stratify Clozapine Dosing

키워드

참고문헌 (195)

1. de Leon J, "Reflections on US psychiatry : how the baton was passed from European psychiatry and the contributions of US psychiatry", J Nerv Ment Dis, 209, pp.403~408 (2021)
2. Borchers AT, "The history and contemporary challenges of the US Food and Drug Administration", Clin Ther, 29, pp.1~16 (2007)
3. de Leon J, "An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s", Eur Arch Psychiatry Clin Neurosci, 272, pp.537~540 (2022)
4. Idänpään-Heikkilä J, "Letter : clozapine and agranulocytosis", Lancet, 2, pp.611~ (1975)
5. Kane J, "Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine", Arch Gen Psychiatry, 45, pp.789~796 (1988)
6. "Clozapine tablet"[URL]
7. Marder SR, "The American Psychiatric Association textbook of psychopharmacology", pp.623~648 (2017), American Psychiatric Association Publishing
8. Meyer JM, "The clozapine handbook : Stahl’s handbooks" (2019), Cambridge University Press
9. Meltzer HY, "Clozapine : balancing safety with superior antipsychotic efficacy", Clin Schizophr Relat Psychoses, 6, pp.134~144 (2012)
10. Michael L, "The undoing project: a friendship that changed our minds" (2017), W. W. Norton & Company
11. Jose de Leon, "Is Psychiatry Scientific? A Letter to a 21st Century Psychiatry Resident", PSYCHIATRY INVESTIGATION, 10(3), pp.205~217 (2013), 대한신경정신의학회[DOI]
12. de Leon J, "Is psychiatry only neurology? Or only abnormal psychology? Déjà vu after 100 years", Acta Neuropsychiatr, 27, pp.69~81 (2015)
13. Ban TA, "The role of serendipity in drug discovery", Dialogues Clin Neurosci, 8, pp.335~344 (2006)
14. de Leon J, "The future(or lack of future)of personalized prescription in psychiatry", Pharmacol Res, 59, pp.81~89 (2009)
15. de Bartolomeis A, "Clozapine’s multiple cellular mechanisms: what do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia", Pharmacol Ther, 236, pp.108236~ (2022)
16. Wagner JG, "History of pharmacokinetics", Pharmacol Ther, 12, pp.537~562 (1981)
17. Meyer UA, "Pharmacogenetics-five decades of therapeutic lessons from genetic diversity", Nat Rev Genet, 5, pp.669~676 (2004)
18. Alexanderson B, "Steady-state plasma levels of nortriptyline in twins : influence of genetic factors and drug therapy", Br Med J, 4, pp.764~768 (1969)
19. Johansson I, "Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine", Proc Natl Acad Sci U S A, 90, pp.11825~11829 (1993)
20. de Leon J, "Phenoconversion and therapeutic drug monitoring", Br J Clin Pharmacol, 80, pp.777~778 (2015)
21. de Leon J, "Precision psychiatry : the complexity of personalizing antipsychotic dosing", Eur Neuropsychopharmacol, 58, pp.80~85 (2022)
22. Baumann P, "The AGNP-TDM expert group consensus guidelines : therapeutic drug monitoring in psychiatry", Pharmacopsychiatry, 37, pp.243~265 (2004)
23. Hiemke C, "AGNP consensus guidelines for therapeutic drug monitoring in psychiatry : update 2011", Pharmacopsychiatry, 44, pp.195~235 (2011)
24. Hiemke C, "Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology : update 2017", Pharmacopsychiatry, 51, pp.9~62 (2018)
25. Spina E, "Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics", Expert Opin Drug Metab Toxicol, 12, pp.407~422 (2016)
26. Schulte P, "What is an adequate trial with clozapine? : therapeutic drug monitoring and time to response in treatment-refractory schizophrenia", Clin Pharmacokinet, 42, pp.607~618 (2003)
27. de Leon J, "A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology", Psychother Psychosom, 89, pp.200~214 (2020)
28. de Leon J, "An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels", Pharmacopsychiatry, 55, pp.73~86 (2022)
29. Ruan CJ, "Clozapine metabolism in East Asians and Caucasians : a pilot exploration of the prevalence of poor metabolizers and a systematic review", J Clin Psychopharmacol, 39, pp.135~144 (2019)
30. Ruan CJ, "Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?", Pharmacogenomics, 21, pp.369~373 (2020)
31. de Leon J, "Promoting safer clozapine dosing in the Americas", Braz J Psychiatry, 44, pp.363~365 (2022)
32. Spina E, "Clinical applications of CYP genotyping in psychiatry", J Neural Transm(Vienna), 122, pp.5~28 (2015)
33. Ruan CJ, "Exploring the prevalence of clozapine phenotypic poor metabolizers in 4Asian samples : they ranged between 2% and 13%", J Clin Psychopharmacol, 39, pp.644~648 (2019)
34. Ito M, "Functional characterization of 20 allelic variants of CYP1A2", Drug Metab Pharmacokinet, 30, pp.247~252 (2015)
35. Soyama A, "Single nucleotide polymorphisms and haplotypes of CYP1A2in a Japanese population", Drug Metab Pharmacokinet, 20, pp.24~33 (2005)
36. Allorge D, "Identification of a novel splice-site mutation in the CYP1A2gene", Br J Clin Pharmacol, 56, pp.341~344 (2003)
37. Zhou Y, "Worldwide distribution of cytochrome P450 alleles : a meta-analysis of population-scale sequencing projects", Clin Pharmacol Ther, 102, pp.688~700 (2017)
38. Diaz FJ, "The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial", J Clin Psychopharmacol, 38, pp.442~446 (2018)
39. Rostami-Hodjegan A, "Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations : a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients", J Clin Psychopharmacol, 24, pp.70~78 (2004)
40. Kuzin M, "Body mass index as a determinant of clozapine plasma concentrations : a pharmacokinetic-based hypothesis", J Psychopharmacol, 35, pp.273~278 (2021)
41. Zarezadeh M, "The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s : a systematic review of current evidence on human studies", Eur J Nutr, 60, pp.2905~2921 (2021)
42. de Leon J, "Serious respiratory infections can increase clozapine levels and contribute to side effects : a case report", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.1059~1063 (2003)
43. Pfuhlmann B, "Toxic clozapine serum levels during inflammatory reactions", J Clin Psychopharmacol, 29, pp.392~394 (2009)
44. de Leon J, "Clozapine is strongly associated with the risk of pneumonia and inflammation", Gen Psychiatr, 33, pp.e100183~ (2020)
45. Clark SR, "Elevated clozapine levels associated with infection : a systematic review", Schizophr Res, 192, pp.50~56 (2018)
46. Ruan CJ, "Around 3% of 1, 300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24, 000 days of clozapine treatment", Psychother Psychosom, 89, pp.255~257 (2020)
47. Arrojo-Romero M, "A Covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine patients : elevations in their plasma clozapine levels", Rev Psiquiatr Salud Ment, 15, pp.290~292 (2022)
48. Lazary J, "Adherence to psychiatric medications : comparing patients with schizophrenia, bipolar disorder and major depression", Neuropsychopharmacol Hung, 23, pp.363~373 (2021)
49. Bender S, "Very high cytochrome P4501A2 activity and nonresponse to clozapine", Arch Gen Psychiatry, 55, pp.1048~1050 (1998)
50. Riesselman A, "A case report that suggested that aspirin’s effects on valproic acid metabolism may contribute to valproic acid’s inducer effects on clozapine metabolism", J Clin Psychopharmacol, 33, pp.812~814 (2013)
51. de Leon J, "The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II : pharmacological issues and further understanding", Rev Psiquiatr Salud Ment, 8, pp.167~188 (2015)
52. Chopra N, "High doses of drugs extensively metabolized by CYP3A4 were needed to reach therapeutic concentrations in two patients taking inducers", Rev Colomb Psiquiatr(Engl Ed), 49, pp.84~95 (2020)
53. Jackson J, "A case report that suggested that the patient was very sensitive to induction and needed 1600mg", d of lamotrigine to get therapeutic concentrations, 2015, pp.35, 745~747
54. Arrojo-Romero M, "Caffeine consumption in a long-term psychiatric hospital : tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use", Schizophr Res, 164, pp.234~241 (2015)
55. Bertilsson L, "Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test", Br J Clin Pharmacol, 38, pp.471~473 (1994)
56. Jerling M, "Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine : evidence from a therapeutic drug monitoring service", Ther Drug Monit, 16, pp.368~374 (1994)
57. Flockhart DA, "Drug interactions, cardiac toxicity, and terfenadine : from bench to clinic?", J Clin Psychopharmacol, 16, pp.101~103 (1996)
58. Issa AM, "Drug withdrawals in the United States : a systematic review of the evidence and analysis of trends", Curr Drug Saf, 2, pp.177~185 (2007)
59. Lesko LJ, "Optimizing the science of drug development : opportunities for better candidate selection and accelerated evaluation in humans", J Clin Pharmacol, 40, pp.803~814 (2000)
60. de Leon J, "Highlights of drug package inserts and the website DailyMed : the need for further improvement in package inserts to help busy prescribers", J Clin Psychopharmacol, 31, pp.263~265 (2011)
61. McGrane I, "Pharmacokinetic drug interactions with oral haloperidol in adults : dose correction factors from a combined weighted analysis", Expert Opin Drug Metab Toxicol, 18, pp.135~149 (2022)
62. de Leon J, "CYP2D6 pharmacogenetics and risperidone : reflections after 25 years of research", Pharmacogenomics, 21, pp.1139~1144 (2020)
63. de Leon J, "Dose and safety concerns of clozapine : worldwide package inserts need revisions", Schizophr Res, 216, pp.2~4 (2020)
64. "Pharmacogenetic Guidelines"[URL]
65. Shader RI, "Some thoughts on pharmacovigilance and postmarketing surveillance", Clin Ther, 38, pp.2509~2510 (2016)
66. Montastruc JL, "What is pharmacoepidemiology? Definition, methods, interest and clinical applications", Therapie, 74, pp.169~174 (2019)
67. De Las Cuevas C, "Clozapine-associated myocarditis in the World Health Organization’s pharmacovigilance database: focus on reports from various countries", Rev Psiquiatr Salud Ment(Engl Ed), 15, pp.238~250 (2002)
68. de Leon J, "According to the WHO clozapine pharmacovigilance database, the United Kingdom accounts for 968 fatal outcomes versus 892 in the rest of the world", Br J Clin Pharmacol, 88, pp.5434~5435 (2022)
69. Simpson GM, "Clozapine--a new antipsychotic agent", Curr Ther Res Clin Exp, 16, pp.679~686 (1974)
70. Leung JG, "The modernization of clozapine : a recapitulation of the past in the United States and the view forward", J Clin Psychopharmacol, 42, pp.565~580 (2022)
71. Moore TJ, "Serious adverse drug events reported to the Food and Drug Administration, 1998-2005", Arch Intern Med, 167, pp.1752~1759 (2007)
72. de Leon J, "Clozapine and the risk of haematological malignancies", Lancet Psychiatry, 9, pp.537~538 (2002)
73. Schoretsanitis G, "An update on the complex relationship between clozapine and pneumonia", Expert Rev Clin Pharmacol, 14, pp.145~149 (2021)
74. Villasante-Tezanos AG, "Pneumonia risk : approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia", Acta Psychiatr Scand, 142, pp.66~67 (2020)
75. de Leon J, "Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics", World Psychiatry, 19, pp.120~121 (2020)
76. de Leon J, "Reflections on the complex history of the concept of clozapine-induced inflammation during titration", Psychiatr Danub, 34, pp.411~421 (2022)
77. Røge R, "Immunomodulatory effects of clozapine and their clinical implications : what have we learned so far?", Schizophr Res, 140, pp.204~213 (2012)
78. Blum A, "Rises in temperature and changes of blood protein fractions under therapy with neuroleptics – with special regard to the new dibenzodiazepine derivative clozapine", Pharmacopsychiatry, 5, pp.155~169 (1972)
79. Gaertner HJ, "Side effects of clozapine", Psychopharmacology (Berl), 99(Suppl 1), pp.S97~S100 (1989)
80. Naber D, "Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients", Psychopharmacology (Berl), 99(Suppl 1), pp.S73~S76 (1989)
81. Helmchen H, "Clinical experience with clozapine in Germany", Psychopharmacology (Berl), 99(Suppl 1), pp.S80~S83 (1989)
82. Safferman A, "Update on the clinical efficacy and side effects of clozapine", Schizophr Bull, 17, pp.247~261 (1991)
83. Pui-yin Chung J, "The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong", Can J Psychiatry, 53, pp.857~862 (2008)
84. Schoretsanitis G, "Adding oral contraceptives to clozapine may require halving the clozapine dose : a new case and a literature review", J Clin Psychopharmacol, 40, pp.308~310 (2020)
85. Vesterby A, "Sudden death during treatment with clozapine (Leponex)", Ugeskr Laeger, 142, pp.170~171 (1980)
86. Meeker JE, "Clozapine tissue concentrations following an apparent suicidal overdose of clozaril", J Anal Toxicol, 16, pp.54~56 (1992)
87. Jensen VE, "Allergic myocarditis in clozapine treatment", Ugeskr Laeger, 156, pp.4151~4152 (1994)
88. Chopra N, "Clozapine-induced myocarditis may be associated with rapid titration : a case report verified with autopsy", Int J Psychiatry Med, 51, pp.104~115 (2016)
89. Committee on Safety of Medicines, "Myocarditis with antipsychotics : recent cases with clozapine(clozaril)", Current Problems in Pharmacovigilance, 19, pp.9~10 (1993)
90. Kilian JG, "Myocarditis and cardiomyopathy associated with clozapine", Lancet, 354, pp.1841~1845 (1999)
91. Coulter DM, "Antipsychotic drugs and heart muscle disorder in international pharmacovigilance : data mining study", BMJ, 322, pp.1207~1209 (2001)
92. La Grenade L, "Myocarditis and cardiomyopathy associated with clozapine use in the United States", N Engl J Med, 345, pp.224~225 (2001)
93. Devarajan S, "Clozapine and sudden death", Lancet, 355, pp.841~ (2000)
94. Hägg S, "Myocarditis related to clozapine treatment", J Clin Psychopharmacol, 21, pp.382~388 (2001)
95. Cohen D, "Beyond white blood cell monitoring : screening in the initial phase of clozapine therapy", J Clin Psychiatry, 73, pp.1307~1312 (2012)
96. Ronaldson KJ, "Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine : a case-control study", Schizophr Res, 141, pp.173~178 (2012)
97. Siskind D, "Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy", Aust N Z J Psychiatry, 54, pp.467~481 (2020)
98. Ronaldson KJ, "Clozapine-induced myocarditis, a widely overlooked adverse reaction", Acta Psychiatr Scand, 132, pp.231~240 (2015)
99. Rohde C, "Adverse cardiac events in out-patients initiating clozapine treatment : a nationwide register-based study", Acta Psychiatr Scand, 137, pp.47~53 (2018)
100. de Leon J, "The history of clozapine in clinical practice : from its introduction to a guideline proposing personalized titrations", J Psychopharmacol, 36, pp.657~660 (2022)
101. de Leon J, "Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations", Acta Psychiatr Scand, 132, pp.242~243 (2015)
102. Freudenreich O, "Clozapine-induced myocarditis : prescribe safely but do prescribe", Acta Psychiatr Scand, 132, pp.240~241 (2015)
103. Verdoux H, "Clinical determinants of fever in clozapine users and implications for treatment management : a narrative review", Schizophr Res, 211, pp.1~9 (2019)
104. de Filippis R, "47 novel cases", Eur Neuropsychopharmacol, 60, pp.25~37 (2022)
105. Nielsen R, "Tracing the peopling of the world through genomics", Nature, 541, pp.302~310 (2017)
106. Lang M, "Metabolism of xenobiotics and chemical carcinogenesis", IARC Sci Publ, 148, pp.13~22 (1999)
107. Singh R, ""Asian"phenotype underestimates the genetic diversity of Asia yet overstates its impact on variability in drug disposition and pharmacodynamics", Clin Pharmacol Ther, 105, pp.802~805 (2019)
108. de Leon J, "Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview", Indian J Psychol Med, 42, pp.4~10 (2020)
109. Chang WH, "Clozapine dosages and plasma drug concentrations", J Formos Med Assoc, 96, pp.599~605 (1997)
110. Chong SA, "Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia", Ther Drug Monit, 19, pp.219~223 (1997)
111. Ng CH, "An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels", Int Clin Psychopharmacol, 20, pp.163~168 (2005)
112. Farooq S, "Ethnicity and clozapine metabolism", Br J Psychiatry, 173, pp.87~ (1998)
113. Chong SA, "Contrasting clozapine prescribing patterns in the east and west?", Ann Acad Med Singap, 29, pp.75~78 (2000)
114. Tang YL, "Clozapine in China", Pharmacopsychiatry, 41, pp.1~9 (2008)
115. Shrivastava A, "Prescribing practices of clozapine in India : results of a opinion survey of psychiatrists", Indian J Psychiatry, 51, pp.225~226 (2009)
116. Wang C, "Proper use of clozapine : experiences in China", Shanghai Arch Psychiatry, 24, pp.108~109 (2012)
117. Kane JM, "Clozapine is underutilized", Shanghai Arch Psychiatry, 24, pp.114~115 (2012)
118. Kelly DL, "Current status of clozapine in the United States", Shanghai Arch Psychiatry, 24, pp.110~113 (2012)
119. Xu SW, "Clozapine prescription pattern in patients with schizophrenia in Asia : the REAP survey(2016)", Psychiatry Res, 287, pp.112271~ (2020)
120. Toyoda K, "A descriptive study of 10-year clozapine use from the nationwide database in Japan", Psychiatry Res, 297, pp.113764~ (2021)
121. Lin CH, "Temporal trends in clozapine use at time of discharge among people with schizophrenia at two public psychiatric hospitals in Taiwan, 2006-2017", Sci Rep, 10, pp.17984~ (2020)
122. Ghotbi R, "Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans", Eur J Clin Pharmacol, 63, pp.537~546 (2007)
123. Rajkumar AP, "Clinical predictors of serum clozapine levels in patients with treatmentresistant schizophrenia", Int Clin Psychopharmacol, 28, pp.50~56 (2013)
124. González-Esquivel DF, "Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients", Arzneimittelforschung, 61, pp.335~339 (2011)
125. González-Esquivel DF, "Amerindians may need clozapine dosing similar to that of Asians", Rev Psiquiatr Salud Ment(Engl Ed), 14, pp.177~179 (2021)
126. Chichra A, "De novo seizures, obsessive compulsive symptoms and neutropenias in patients on clozapine : a retrospective cohort study", Ind J Psychol Med, 45, pp.33~37 (2023)
127. Schoretsanitis G, "European whites may need lower minimum therapeutic clozapine doses than those customarily proposed", J Clin Psychopharmacol, 41, pp.140~147 (2021)
128. Gudelsky GA, "Summary of discussions", Psychopharmacology, 99(Suppl 1), pp.S126~S127 (1989)
129. Pollack S, "A comparison of European and American dosing regimens of schizophrenic patients on clozapine : efficacy and side effects", Psychopharmacol Bull, 31, pp.315~320 (1995)
130. Simpson GM, "Double-blind study of clozapine dose response in chronic schizophrenia", Am J Psychiatry, 156, pp.1744~1750 (1999)
131. Zang YN, "The impact of smoking, sex, infection, and comedication administration on oral olanzapine : a population pharmacokinetic model in Chinese psychiatric patients", Eur J Drug Metab Pharmacokinet, 46, pp.353~371 (2021)
132. Bigos KL, "Sex, race, and smoking impact olanzapine exposure", J Clin Pharmacol, 48, pp.157~165 (2008)
133. Flanagan RJ, "Clozapine: dose, sex, ethnicity, smoking habit, age, body weight, and plasma clozapine and Ndesmethylclozapine (norclozapine) concentrations in clinical practice", J Clin Psychopharmacol (2023)[DOI]
134. Juul Povlsen U, "Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years", Acta Psychiatr Scand, 71, pp.176~185 (1985)
135. Lindström LH, "The effect of long-term treatment with clozapine in schizophrenia : a retrospective study in 96 patients treated with clozapine for up to 13 years", Acta Psychiatr Scand, 77, pp.524~529 (1988)
136. Lilleng P, "Clozapine and myocarditis", Tidsskr Nor Laegeforen, 115, pp.3026~3027 (1995)
137. van der Zalm Y, "Clozapine and mortality : a comparison with other antipsychotics in a nationwide Danish cohort study", Acta Psychiatr Scand, 143, pp.216~226 (2021)
138. Nanko S, "Why is clozapine not available in Japan?", Lancet, 341, pp.490~ (1993)
139. Berger D, "Psychiatric drug development in Japan", Science, 273, pp.318~319 (1996)
140. Shimazawa R, "Delays in psychiatric drug development in Japan", J Clin Pharm Ther, 37, pp.348~351 (2012)
141. Yasui-Furukori N, "Japanese patients need slower, personalized clozapine titrations : a comment on the case described by Kikuchi et al", PCN Reports, 2, pp.e70~ (2023)
142. Kishi T, "Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia : results from a 12-week, flexible dose study using raters masked to antipsychotic choice", Asian J Psychiatr, 6, pp.200~207 (2013)
143. Tsukahara M, "Clinical utility and safety of slower-than-recommended titration of clozapine for treatment-resistant schizophrenia : a retrospective cohort study", Psychiatr Q, 92, pp.703~713 (2021)
144. Kikuchi Y, "Clozapine-induced cardiomyopathy : a first case in Japan", Schizophr Res, 150, pp.586~587 (2013)
145. Otsuka Y, "Clozapine-induced myocarditis : follow-up for 3. 5 years after successful retrial", J Gen Fam Med, 20, pp.114~117 (2019)
146. Kikuchi Y, "Successful rechallenge with clozapine after discontinuation due to drug-induced pneumonia : a case report", PCN Reports, 1, pp.e38~ (2022)
147. Higgins JM, "Incidence and management of clozapine-induced myocarditis in a large tertiary hospital", Can J Psychiatry, 64, pp.561~567 (2019)
148. Sandarsh S, "Monitoring for myocarditis during treatment initiation with clozapine", Acta Psychiatr Scand, 144, pp.194~200 (2021)
149. Bellissima BL, "Incidence and investigation of potential risk-factors for clozapine-associated myocarditis and cardiomyopathy in a New Zealand cohort", Psychiatry Res, 299, pp.113873~ (2021)
150. Berk M, "Monitoring the safe use of clozapine : a consensus view from Victoria, Australia", CNS Drugs, 21, pp.117~127 (2007)
151. Vickers M, "Risk factors for clozapine-induced myocarditis and cardiomyopathy : a systematic review and meta-analysis", Acta Psychiatr Scand, 145, pp.442~455 (2022)
152. de Leon J, "Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and", or inhibitory effects may vary with time, the individual, and the autoinduction of valproic acid, 2020, pp.42, 159~161
153. Ertuğrul A, "Valproate, obesity and other causes of clozapine poor metabolism in the context of rapid titration may explain clozapine-induced myocarditis: a re-analysis of a Turkish case series", Rev Psiquiatr Salud Ment(Engl Ed), 15, pp.281~286 (2022)
154. Koenig M, "Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases", Neuropsychopharmacol Hung, 24, pp.29~41 (2022)
155. Winckel K, "Clozapine-induced myocarditis : separating the wheat from the chaff", Aust N Z J Psychiatry, 49, pp.188~ (2015)
156. Nachmani Major N, "Implementation and outcomes of a clozapine-associated myocarditis screening program in a region of South Australia—lessons learned", J Clin Psychopharmacol, 40, pp.250~258 (2020)
157. De Las Cuevas C, "Association between myocarditis and antipsychotics other than clozapine : a systematic literature review and a pharmacovigilance study using VigiBase", Expert Rev Clin Pharmacol, 15, pp.65~78 (2022)
158. Mostafa S, "An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic(PGx)variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1genes", J Neural Transm(Vienna), 126, pp.5~18 (2019)
159. "Psychosis and schizophrenia in adults: treatment and management"[URL]
160. Taylor DM, "The Maudsley prescribing guidelines in psychiatry" (2021), Wiley-Blackwell
161. Rajagopal S, "Clozapine, agranulocytosis, and benign ethnic neutropenia", Postgrad Med J, 81, pp.545~546 (2005)
162. Taylor D, "Distinctive pattern of neutrophil count change in clozapine-associated, lifethreatening agranulocytosis", Schizophrenia(Heidelb), 8, pp.21~ (2022)
163. Oloyede E, "Relaxation of the criteria for entry to the UK clozapine central non-rechallenge database : a modelling study", Lancet Psychiatry, 9, pp.636~644 (2022)
164. Segev A, "Clozapine-induced myocarditis : electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy", Br J Psychiatry, 219, pp.644~651 (2021)
165. Handley SA, "Clozapine-induced gastrointestinal hypomotility : presenting features and outcomes, UK pharmacovigilance reports, 1992-2017", Br J Psychiatry, 220, pp.355~363 (2022)
166. Taylor DM, "Reasons for discontinuing clozapine : matched, case-control comparison with risperidone long-acting injection", Br J Psychiatry, 194, pp.165~167 (2009)
167. Montastruc JL, "Fatal adverse drug reactions : a worldwide perspective in the World Health Organization pharmacovigilance database", Br J Clin Pharmacol, 87, pp.4334~4340 (2021)
168. De Leon J, "Data from the World Health Organization’s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions", Schizophr Bull, 46, pp.1~3 (2020)
169. Whiskey E, "An evaluation of the variation and underuse of clozapine in the United Kingdom", Acta Psychiatr Scand, 143, pp.339~347 (2021)
170. Iqbal E, "The side effect profile of clozapine in real world data of three large mental health hospitals", PLoS One, 15, pp.e0243437~ (2020)
171. de Freitas DF, "Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia : a retrospective cohort study using data from electronic clinical records", Soc Psychiatry Psychiatr Epidemiol, 57, pp.1341~1355 (2022)
172. Taylor DM, "Prescribing of clozapine and olanzapine : dosage, polypharmacy and patient ethnicity", Psychiatr Bull, 28, pp.241~243 (2004)
173. Schoretsanitis G, "Best practices for starting clozapine in patients with schizophrenia : how to switch from the prior antipsychotic(s)", J Clin Psychiatry, 83, pp.22~ (2022)
174. de Leon J, "An international clozapine titration guideline for clozapine : an opportunity for moving forward on personalizing clozapine treatment in India and other countries", Indian J Psychiatry, 64, pp.331~334 (2022)
175. de Leon J, "An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine", Gen Psychiatr, 35, pp.e100773~ (2022)
176. Mcneil JJ, "Clozapine-induced myocarditis : characterisation using case-control design", Eur Heart J, 34(suppl 1), pp.P3863~ (2013)
177. Popper K, "Conjectures and refutations" (1963), Harper Torchbooks
178. Joyce PR, "The medical model-why psychiatry is a branch of medicine", Aust N Z J Psychiatry, 14, pp.269~278 (1980)
179. Chen CH, "Ethnopsychopharmacology", Int Rev Psychiatry, 20, pp.452~459 (2008)
180. Dean L, "Medical genetics summaries" (2012), National Center for Biotechnology Information (US)
181. Zubiaur P, "Association between CYP2C19and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam", Biomed Pharmacother, 155, pp.113747~ (2022)
182. Inomata S, "CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia", Clin Pharmacol Ther, 78, pp.647~655 (2005)
183. Desta Z, "Clinical significance of the cytochrome P450 2C19 genetic polymorphism", Clin Pharmacokinet, 41, pp.913~958 (2002)
184. Inada T, "Efficacy of diazepam as an anti-anxiety agent : meta-analysis of double-blind, randomized controlled trials carried out in Japan", Hum Psychopharmacol, 18, pp.483~487 (2003)
185. Zhou Y, "Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing", Clin Pharmacol Ther, 109, pp.160~174 (2021)
186. Crettol S, "Pharmacogenomics in psychiatry : from therapeutic drug monitoring to genomic medicine", Clin Pharmacol Ther, 95, pp.254~257 (2014)
187. Nakaoka H, "Distribution of HLA haplotypes across Japanese archipelago : similarity, difference and admixture", J Hum Genet, 60, pp.683~690 (2015)
188. Sathirakul K, "Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects", Br J Clin Pharmacol, 56, pp.184~187 (2003)
189. Kudo S, "Pharmacokinetics of haloperidol : an update", Clin Pharmacokinet, 37, pp.435~456 (1999)
190. Kato Y, "Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution", Drug Metab Dispos, 40, pp.240~248 (2012)
191. Lin SK, "Racial", ethnic differences in the pharmacokinetics of antipsychotics : focusing on East Asians, 2022, pp.12, 1362~
192. de Leon J, "Using therapeutic drug monitoring to personalize clozapine dosing in Asians", Asia Pac Psychiatry, 12, pp.e12384~ (2020)
193. Kirilochev OO, "Clozapine-induced myocarditis in Russia: animal studies but no clinical studies", Rev Psiquiatr Salud Ment(Engl Ed), 15, pp.294~295 (2022)
194. Vost K, "St. Albert the great: champion of faith & reason" (2011), Tan Books
195. Danilewitz M, "Successful clozapine rechallenge after suspected clozapine-associated myocarditis : a case report", J Clin Psychopharmacol, 41, pp.218~220 (2021)

관련 논문AI추천